Manulife (Manufacturers Life Insurance)
TSHA icon

Manulife (Manufacturers Life Insurance)’s Taysha Gene Therapies TSHA Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$444K Buy
99,371
+32,286
+48% +$150K ﹤0.01% 2211
2025
Q4 		$369K Sell
67,085
-2,772
-4% -$13.5K ﹤0.01% 2291
2025
Q3 		$228K Buy
69,857
+8,852
+15% +$25.1K ﹤0.01% 2508
2025
Q2 		$141K Sell
61,005
-2,792
-4% -$6.07K ﹤0.01% 2677
2025
Q1 		$88.7K Buy
63,797
+786
+1% +$1.31K ﹤0.01% 2724
2024
Q4 		$109K Buy
63,011
+2,346
+4% +$4.87K ﹤0.01% 2800
2024
Q3 		$122K Sell
60,665
-72,548
-54% -$159K ﹤0.01% 2814
2024
Q2 		$298K Buy
133,213
+69,487
+109% +$202K ﹤0.01% 2425
2024
Q1 		$183K Buy
63,726
+2,179
+4% +$4.54K ﹤0.01% 2626
2023
Q4 		$109K Hold
61,547
– – ﹤0.01% 2793
2023
Q3 		$194K Buy
+61,547
New +$115K ﹤0.01% 2619
2022
Q2 		– Sell
-11,233
Closed -$73.2K – 3142
2022
Q1 		$73.2K Sell
11,233
-1,731
-13% -$12.9K ﹤0.01% 3005
2021
Q4 		$151 Buy
12,964
+650
+5% +$9.8K ﹤0.01% 2986
2021
Q3 		$229K Sell
12,314
-651
-5% -$12.4K ﹤0.01% 2886
2021
Q2 		$275K Buy
+12,965
New +$299K ﹤0.01% 2875

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Manulife (Manufacturers Life Insurance)'s TSHA Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) increased its Taysha Gene Therapies (TSHA) stake by 48% in Q1 2026, buying an estimated $150K and bringing the position to 99,371 shares worth $444K. The position accounts for ﹤0.01% of the portfolio, ranked #2211.

Manulife (Manufacturers Life Insurance) first reported a position in TSHA in Q2 2021 and has held it in 15 quarters since. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 99,371 shares of Taysha Gene Therapies worth $444K as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) bought 32,286 Taysha Gene Therapies shares in Q1 2026, an estimated $150K.
  • Taysha Gene Therapies made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #2211 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Taysha Gene Therapies in Q2 2021 and has held it in 15 quarters since.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.